Novel Therapeutics for Hepatocellular Carcinoma
Clinics in Liver Disease · 2025
DOI: 10.1016/j.cld.2025.06.009 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinics in Liver Disease, 2025. Verfasst von Mohamed I Elsaid und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Biostatistics and Population Health, Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, …. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Immunotherapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 155 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Genentech, AstraZeneca United States.
Abstract (Originalsprache)
Recent advances have transformed the therapeutic landscape for advanced hepatocellular carcinoma (HCC). Immunotherapy combinations, such as atezolizumab-bevacizumab, ipilimumab-nivolumab, and STRIDE, have raised survival expectations, while novel checkpoints (LAG-3, TIGIT, TIM-3) and targeted therapies addressing FGFR4 and β-catenin are entering late-phase trials. Additionally, metabolic and stress-pathway inhibitors targeting ferroptosis, GLS1, NRF2, and YAP-TAZ show promising synergy with existing treatments. Precision oncology innovations, including liquid biopsy and AI-driven imaging, further enhance patient-tailored approaches. Addressing equity and global implementation barriers will ensure these advances benefit all patients, marking a decisive shift toward personalized and equitable HCC care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Biostatistics and Population Health, Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, USA; Division of Medical Oncology, Department of Internal Medicine, Co…
- Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA.
Förderung
- NCI NIH HHS
- Genentech
- AstraZeneca United States
- NIH National Cancer Institute
Zitieren
APA
Elsaid, M. I., & Manne, A. (2025). Novel Therapeutics for Hepatocellular Carcinoma. Clinics in Liver Disease. https://doi.org/10.1016/j.cld.2025.06.009
Vancouver
Elsaid MI, Manne A. Novel Therapeutics for Hepatocellular Carcinoma. Clinics in Liver Disease. 2025. doi:10.1016/j.cld.2025.06.009
BibTeX
@article{Elsaid2025,
author = {Elsaid, Mohamed I and Manne, Ashish},
title = {Novel Therapeutics for Hepatocellular Carcinoma},
journal = {Clinics in Liver Disease},
year = {2025},
doi = {10.1016/j.cld.2025.06.009}
}
EUVIMED